Navigation Links
Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010
Date:11/2/2010

Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference... -- POINT RICHMOND, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010

 
Download image

POINT RICHMOND, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Thursday, November 11, 2010 at 5:00 p.m. Eastern time to discuss its third quarter 2010 financial results.  The conference call will follow the release of the Transcept third quarter 2010 financial results after the close of market that day.

(Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101102/SF93452LOGO)Conference Call Information Date: Thursday, November 11, 2010Time: 5:00 p.m. ESTDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through December 17, 2010.

A telephone replay of the conference call will be available shortly after the conclusion of the call through November 19, 2010.  The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 22330914.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep.  In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA.  Transcept plans to resubmit the Intermezzo® NDA in the first quarter of 2011, and anticipates a six-month review by the FDA. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include our plan to resubmit the Intermezzo® NDA in the first quarter of 2011 and to begin a Phase 2, double-blind, placebo-controlled study of TO-2061 in 2011.  Transcept may not actually carryout these plans. Various important factors that could cause actual events to differ materially from the forward-looking statements that Transcept makes, include delays in compiling the contents of the planned Intermezzo® NDA resubmission, the outcomes from Phase 1 studies of TO-2061; dependence on third parties to manufacture TO-2061 and carry-out the planned study; success in our efforts to seek approval for Intermezzo®, our lead product candidate, and the business of Transcept generally.  These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
3. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
4. Transcept Pharmaceuticals to Present at BIO Investor Forum
5. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
6. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
7. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
8. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
9. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
11. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):